Can CAR-T therapies for solid tumors be safe?
Yes, but safety is a major concern that researchers are actively addressing. The most common serious side effects are cytokine release syndrome (CRS)—a systemic inflammatory response causing fever and low blood pressure—and neurotoxicity (ICANS), which can range from confusion to seizures. One review reports CRS occurs in 40–95% of patients and neurotoxicity in 15–65% [1]. In solid tumors, on-target, off-tumor toxicity is a particular risk because many tumor antigens are also found on healthy tissues [11]. For example, targeting HER2 can damage heart tissue, and targeting mesothelin can affect the lining of the lungs and abdomen.
Several engineering strategies are being tested to improve safety. One approach uses a 'tunable safety switch' with the drug dasatinib, which can reversibly inhibit CAR T-cell activity without killing the cells. In mouse models of lung adenocarcinoma, daily dasatinib stopped tumor regression, but when the drug was stopped, the CAR T cells resumed their anti-tumor activity [9]. Another study co-expressed SMAD7 in CAR T cells to block TGF-β signaling, which reduced inflammatory cytokine production and improved safety in mouse models [7]. A third approach uses a fibrin glue carrier for local delivery after surgery, which minimized on-target off-tumor toxicity and did not impair wound healing in mice [8]. These strategies aim to make CAR T therapy safer without sacrificing effectiveness.
Can CAR-T therapies for solid tumors produce durable responses?
Durability is a key challenge, but recent innovations show promise. The main barriers are T-cell exhaustion (where CAR T cells lose function over time) and the immunosuppressive tumor microenvironment (TME) that shuts down immune activity. One breakthrough study engineered CAR T cells to secrete interleukin-10 (IL-10), which preserved mitochondrial function and prevented exhaustion. In mouse models of colon, breast, melanoma, and pancreatic cancer, these IL-10 CAR T cells led to complete tumor regression and long-lasting immune protection against tumor rechallenge [3]. Another study used an oncolytic virus to deliver a CD19 antigen tag to pancreatic tumors, making them visible to CD19-targeted CAR T cells. This combination caused significant tumor regression (128 mm³ vs 485 mm³ in controls) and turned 'cold' tumors 'hot' [2].
However, durability in humans remains limited. A review of clinical trials notes that antigen loss and heterogeneity—where some tumor cells stop expressing the target—allow tumors to relapse [6]. One strategy to counter this is multi-antigen targeting, where CAR T cells are designed to recognize several tumor markers at once [4]. Another approach uses probiotic bacteria that colonize tumors and release synthetic targets, enabling CAR T cells to kill cancer cells regardless of their original antigens [10]. These methods are still in preclinical or early clinical stages, so while the science is promising, durable responses in patients have not yet been consistently achieved.
Who benefits most, and under what conditions?
Based on current evidence, patients with solid tumors that have specific, well-defined antigens and a less hostile tumor microenvironment are most likely to benefit. For example, CAR T cells targeting HER2, mesothelin, or EGFRvIII have shown activity in breast, pancreatic, and brain cancers, respectively [8][12]. However, success is highest when CAR T cells are combined with other therapies that overcome the TME, such as oncolytic viruses [2], checkpoint inhibitors [4], or local delivery methods like fibrin glue [8].
The most promising results come from studies that engineer CAR T cells to resist exhaustion or improve trafficking. For instance, IL-10-secreting CAR T cells worked across multiple cancer types in mice, suggesting broad applicability [3]. Similarly, SMAD7-expressing CAR T cells maintained function even in high-TGF-β environments, which are common in many solid tumors [7]. In brain cancer, early clinical trials have shown safety and some disease-modifying activity, but responses are not yet durable [12]. Overall, the field is moving toward personalized combinations—matching the right CAR design, delivery method, and adjunct therapy to each tumor type—but no single approach works for all patients yet.
About These Sources
This answer is built on 12 peer-reviewed studies — published from 2023 to 2026, 9 from 2024 or later, 10 in Q1 journals, collectively cited 788 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 63 papers retrieved from a database of over 500 million.
Sources used in this answer
CAR T Cells and T-Cell Therapies for Cancer
Reviews FDA-approved CAR T therapies for blood cancers and notes no solid tumor approvals; CRS occurs in 40–95% of patients, neurotoxicity in 15–65%.
Using Oncolytic Virus to Retask CD19-Chimeric Antigen Receptor T Cells for Treatment of Pancreatic Cancer: Toward a Universal Chimeric Antigen Receptor T-Cell Strategy for Solid Tumor.
In a mouse model of pancreatic cancer, an oncolytic virus delivering CD19t enabled CD19-CAR T cells to cause significant tumor regression (128 mm³ vs 485 mm³ control).
IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases
IL-10-secreting CAR T cells preserved mitochondrial function, led to complete regression of established solid tumors and metastases in multiple mouse models, and provided durable immune protection.
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
Reviews advances in CAR T engineering for solid tumors, including cytokine-armored CARs, protease-regulated CARs, and CRISPR-based modifications to improve persistence and reduce toxicity.
In-depth analysis of the safety of CAR-T cell therapy for solid tumors
Analyzes safety of CAR T in solid tumors, highlighting CRS, neurotoxicity, organ toxicity, and long-term risks like secondary malignancies; calls for better management strategies.
CAR-T cells in solid tumors: Challenges and breakthroughs
Reviews challenges in solid tumor CAR T therapy including poor trafficking, limited persistence, antigen loss, and immunosuppressive TME; discusses next-generation engineering approaches.
SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors
SMAD7 co-expression in HER2-targeted CAR T cells reduced inflammatory cytokines, resisted TGF-β-induced exhaustion, and improved persistence and safety in mouse models and patient-derived organoids.
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Local delivery of mesothelin-specific CAR T cells in fibrin glue after incomplete surgery cleared residual cancer cells and improved survival in mice without wound healing complications.
Abstract 3993: A tunable safety switch for solid tumor CAR T-cell therapy
Dasatinib acted as a reversible safety switch for c-KIT-engineered CAR T cells in a lung adenocarcinoma mouse model, inhibiting activity when given and restoring it upon withdrawal.
Probiotic-guided CAR-T cells for solid tumor targeting
Probiotic-guided CAR T cells (ProCARs) used tumor-colonizing bacteria to release synthetic targets, enabling antigen-agnostic lysis in multiple mouse cancer models.
CAR T-Cell Therapy for Solid Tumors
Highlights that antigen overlap between tumors and normal tissues causes on-target off-tumor toxicity, and the immunosuppressive TME limits efficacy; calls for improved antigen selection and trial design.
CAR T cells: engineered immune cells to treat brain cancers and beyond
Reviews CAR T for brain cancers, noting early clinical safety and disease-modifying activity but limited durability; discusses targets like EGFRvIII, IL13Rα2, and HER2.